Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000831

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Apr 23, 2026 207.03M sh
Cash And Equivalents Q3 2025 · Oct 31, 2024 $2.06K
Current Liabilities Q3 2025 · Oct 31, 2024 $3.93M
Current Liabilities Q3 2025 · Jan 31, 2024 $3.49M
Total Liabilities Q3 2025 · Oct 31, 2024 $3.93M
Total Liabilities Q3 2025 · Jan 31, 2024 $3.49M
Current Assets Q3 2025 · Oct 31, 2024 $41.79K
Current Assets Q3 2025 · Jan 31, 2024 $23.63K
Total Assets Q3 2025 · Oct 31, 2024 $58.38K
Total Assets Q3 2025 · Jan 31, 2024 $137.34K
Shares Diluted Q3 2025 · Oct 31, 2023 207.03M sh
Shares Diluted Q3 2025 · Oct 31, 2023 207.03M sh
Operating Cash Flow Q3 2025 · Oct 31, 2023 −$32.3K
Stockholders Equity Q3 2025 · Oct 31, 2023 −$3.17M
Stockholders Equity Q3 2025 · Jul 31, 2023 −$2.97M
Stockholders Equity Q3 2025 · Apr 30, 2023 −$2.66M
Stockholders Equity Q3 2025 · Jan 31, 2023 −$2.4M
Eps Diluted Q3 2025 · Oct 31, 2023 $0.00
Eps Diluted Q3 2025 · Oct 31, 2023 $0.00
Sga Expense Q3 2025 · Oct 31, 2023 $234.98K
Sga Expense Q3 2025 · Oct 31, 2023 $893.16K
Net Income Q3 2025 · Oct 31, 2023 −$234.98K
Net Income Q3 2025 · Oct 31, 2023 −$893.16K
Net Income Q3 2025 · Jul 31, 2023 −$353.58K
Net Income Q3 2025 · Apr 30, 2023 −$304.6K
Operating Income Q3 2025 · Oct 31, 2023 −$234.98K
Operating Income Q3 2025 · Oct 31, 2023 −$893.16K
Revenue Q3 2025 · Oct 31, 2023 $0
Revenue Q3 2025 · Oct 31, 2023 $0